𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma : A Southwest Oncology Group Phase II study

✍ Scribed by Laurence Elias; Danika Lew; Robert A. Figlin; Robert C. Flanigan; Mark E. Thompson; Pierre L. Triozzi; Robert J. Belt; David P. Wood Jr.; Saul E. Rivkin; E. David Crawford


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
87 KB
Volume
89
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


A phase II trial of interferon-α and 5-f
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Phase II trial of 5-fluorouracil, interf
✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

Phase II study of 5-fluorouracil and fol
✍ Giuseppe Colucci 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our

Evaluation of low dose continuous infusi
✍ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

A phase II study of 5-fluorouracil, leuc
✍ Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been ext